Arcutis Biotherapeutics Shares Jump After FDA OKs Skin-Condition Treatment
December 15 2023 - 6:13PM
Dow Jones News
By Ben Glickman
Shares of Arcutis Biotherapeutics rose late Friday after the
company's treatment for a skin condition was approved by the Food
and Drug Administration.
The stock was up 18% to $2.89 in after-hours trading, following
a 3.9% drop at Friday's close. Shares are down about 84% this
year.
Zoryve topical foam has been approved for the treatment of
seborrheic dermatitis, a skin condition which mostly affects the
scalp, the Westlake Village, Calif.-based dermatology company
said.
A cream form of Zoryve was already approved by the FDA for the
topical treatment of plaque psoriasis in patients 6 years of age
and older. Net product revenues for the cream were $8.1 million in
the third quarter, Arcutis reported last month.
Arcutis said it plans to make the topical foam widely available
by the end of next month.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
December 15, 2023 17:58 ET (22:58 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From Apr 2024 to May 2024
Arcutis Biotherapeutics (NASDAQ:ARQT)
Historical Stock Chart
From May 2023 to May 2024
